TCR2 THERAPEUTICS INC.
DelistedCIK 1750019fmd_14WGCS5431M51X5JJR4Y22AV9HManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2018 to Mar 31, 2023, 21 periods
| Line item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|
| Research and development | 20 | 37 | 52 | 74 | 99 |
| Total operating expenses | 26 | 51 | 69 | 100 | 153 |
| Operating income | (26) | (51) | (69) | (100) | (153) |
| Other non-operating income (expense) | 2 | 4 | 2 | 0 | 2 |
| Income before taxes | (24) | (47) | (67) | (100) | (152) |
| Income tax expense | – | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | (48) | (67) | (100) | (152) |
| Net income | (24) | (48) | (67) | (100) | (152) |
| Net income to common shareholders | (62) | (97) | (67) | – | – |